Apixaban 2.5 mg Before Spine Surgery: Hold for 48 Hours
For patients on apixaban 2.5 mg twice daily undergoing spinal surgery, hold the medication for at least 48 hours (2 days) before the procedure. Spine surgery is classified as high-bleed-risk surgery due to the potential for catastrophic consequences of epidural bleeding and associated neurological complications.
Preoperative Management
The FDA label for Eliquis explicitly states that apixaban should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding 1. Spine surgery, particularly procedures involving neuraxial anesthesia or spinal instrumentation, falls squarely into this high-risk category.
Rationale Based on Pharmacokinetics
The 48-hour interruption period is based on apixaban's elimination half-life of 7-8 hours 2. Holding the medication for 2 days allows approximately 4-5 half-lives to elapse, resulting in minimal residual anticoagulant effect at the time of surgery 3, 4. The most recent CHEST guidelines (2022) confirm this approach, recommending 2 days off before high-bleed-risk procedures 3, 4.
Special Considerations for Neuraxial Procedures
Spine surgery with neuraxial anesthesia requires particular caution. The risk of epidural or spinal hematoma, though rare, can result in permanent paralysis 1. The FDA label specifically warns that indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last apixaban dose, and the next dose should not be administered earlier than 5 hours after catheter removal 1.
Important Caveats
Renal Function
While the 48-hour hold applies to patients with normal renal function, patients with impaired renal function may require longer interruption periods 2. Apixaban has 25% renal clearance, so severe renal impairment (CrCl <30 mL/min) may necessitate extending the hold beyond 48 hours 3.
No Bridging Required
Bridging anticoagulation with heparin is NOT recommended during the 48-hour interruption period 1. The FDA label explicitly states that "bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required" 1. The rapid offset and onset of DOACs eliminates the need for bridging therapy 3, 4.
Verification of Adequate Interruption
Recent research demonstrates that a 48-hour hold results in clinically insignificant anticoagulation levels in the vast majority of patients. One prospective study found that 94% of patients achieved apixaban concentrations ≤30 ng/mL after discontinuation, with median time between last dose and surgery of 76 hours 5. However, elderly patients with chronic kidney disease may have prolonged drug clearance, with detectable levels persisting beyond expected timeframes 6.
Postoperative Resumption
Resume apixaban 48-72 hours after spine surgery once adequate hemostasis is established 2, 3, 4. For patients at high thromboembolism risk, consider using the reduced dose of 2.5 mg twice daily for the first 2-3 days postoperatively before returning to the patient's usual dose 2.
The FDA label confirms that "ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established" 1.
Clinical Pitfalls to Avoid
- Do not hold for only 24 hours for spine surgery—this is insufficient for high-bleed-risk procedures
- Do not use bridging anticoagulation during the interruption period
- Do not resume apixaban too early postoperatively—wait for confirmed hemostasis
- Do not forget to assess renal function—impaired clearance may require extended interruption
- Do not remove epidural catheters within 24 hours of the last apixaban dose
The 48-hour preoperative hold represents the evidence-based standard for balancing thrombotic and hemorrhagic risks in patients undergoing spine surgery 3, 4, 1.